Failure to Monitor Anticoagulant Therapy Leads to Resident's Decline
Summary
The facility failed to ensure proper monitoring and administration of anticoagulant medication for a resident with a history of atrial fibrillation and an artificial heart valve. The resident was prescribed Coumadin (warfarin) and had previously been treated for a subdural hematoma. Upon admission to the facility, the resident was ordered to resume Coumadin at a higher dose without a neurology consultation. The facility did not conduct the required weekly International Normalized Ratio (INR) tests to ensure the medication was at a therapeutic level. The resident developed significant bruising, which was not identified by the facility as a potential side effect of the anticoagulant medication. An INR test eventually revealed a critically high level, necessitating the administration of Vitamin K to counteract the effects of Coumadin. Despite this, the facility failed to conduct additional INR tests as ordered, and the resident's condition continued to decline. The resident was unable to take medications due to a significant decline in condition and eventually expired. The facility did not have a care plan in place for monitoring the side effects of Coumadin, and there was no documentation of physician notification regarding the resident's condition or the missed INR tests.
Removal Plan
- Regional Nurse Consultant #201 reviewed the records (including Coumadin orders, PT/INR, physician notification) for Resident #24, the only resident on Coumadin at the facility.
- A plan was noted for Resident #24 to have laboratory testing (PT/INR) completed as ordered, PT/INR results reported within eight hours to the physician, signs and symptoms of elevated INRs identified and reported to the physician by a licensed nurse.
- In-service education for licensed nurses by the Director of Nursing (DON) via lecture began on the following topics: anticoagulation policy, signs and symptoms of bleeding related to Coumadin usage, lab policy, and change in resident condition or status which included abnormal labs.
- Seven nurses were educated. The remaining four nurses would be educated before working their next scheduled shift.
- The facility implemented a plan for all newly hired nurses to receive the education prior to working the floor.
- The facility Lab Testing and Results policy was reviewed by the Executive Director and Director of Nursing.
- All 18 Certified Nursing Assistants (CNA) were educated by the DON via lecture on the signs and symptoms of bleeding that must be reported to the charge nurse.
- The facility implemented a plan for all newly hired CNAs to receive the education prior to working the floor.
- MDS Nurse #106 completed a care plan review to ensure signs and symptoms of bleeding were addressed for residents receiving anti-coagulants.
- The facility identified and reviewed the care plan for 10 residents receiving anticoagulant medications.
- The Director of Nursing (DON) or designee would complete audits on all residents receiving Coumadin daily for two weeks, then three times a week for two weeks, then weekly for two weeks and then as needed to ensure PT/INR labs were obtained per order, notification to physician of PT/INR results were within eight hours and to ensure any signs and symptoms of bleeding were noted and reported to the physician as soon as practicable.
- The DON or designee would complete audits of five residents on anti-coagulant therapy three times a week for four weeks to ensure signs and symptoms of bleeding were addressed in the resident's care plan for residents receiving anti-coagulant medications.
- Any concerns identified with the audits will be forwarded to the Quality Assurance (QA) committee weekly for four weeks and as needed for immediate follow-up.
- The administrator will be responsible for ongoing compliance.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.